Comparing the current results to its competitors, Beyond Air Inc reported Revenue increase in the 1 quarter 2026 by 52.94 % year on year. The sales growth was above Beyond Air Inc 's competitors' average revenue growth of 7.74 %, achieved in the same quarter.
Beyond Air Inc 's Comment on Competition and Industry Peers
The competitive landscape includes Shenzhen Respomed Medical Technology, which has developed a device that uses an electric charge to generate nitric oxide. Competitors may possess greater name recognition, financial resources, technical capabilities, manufacturing capacity, marketing expertise, human resources, and more extensive experience and infrastructure in pharmaceutical research, clinical development, regulatory approvals, and global commercialization. To date, no gas-based therapies related to Beyond Cancer's programs or NeuroNos have received approval from the FDA or other regulatory agencies.
Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Bluebird Bio Inc's business model focuses on developing gene therapies for severe genetic diseases and cancer. They collaborate with academic and industry partners to leverage their gene editing and cell-based technologies for discovering potential treatments and advancing these therapies through clinical trials.
Linde Plc operates as a leading global industrial gases and engineering company, focusing on the production and supply of a diverse range of gases such as oxygen, nitrogen, hydrogen, and helium. Its business model emphasizes delivering customized solutions, including gas handling systems and storage solutions, to key sectors like healthcare, chemicals, metallurgy, and manufacturing, ensuring a reliable supply and optimizing operational efficiency for its customers.
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
Sources:
Beyond Air Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Beyond Air Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
